|
Noubar Afeyan is a Co-Founder of LS9 and Managing Partner of Flagship Ventures. He is a technologist, entrepreneur and venture capitalist. He has founded and helped build 15 successful life science and technology startups during the past two decades. In addition, he is a Senior Lecturer at MIT in both the Sloan School of Management and the Biological Engineering Department. Noubar has authored numerous scientific publications as well as patents, and earned his Ph.D. in Biochemical Engineering from MIT in 1987 where he worked on the microbial conversion of cellulosic biomass into ethanol.
In 1999 Noubar co-founded Flagship Ventures, an early stage venture capital and entrepreneurship firm. Prior to that, he participated in creating and launching six highly successful new ventures. He was the Founder, Chairman, and CEO of PerSeptive Biosystems (NASDAQ: PBIO), a leader in the bio-instrumentation field. He also served as Chairman of the Board of ChemGenics Pharmaceuticals, a pioneer in genomics-based drug discovery that was a spin-off company of PerSeptive. After PerSeptive's acquisition by Applera Corporation (NYSE: ABI), he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of their tracking stock subsidiary, Celera Genomics (NYSE: CRA). He has also been a founding team member, investor and active board member/advisor of Antigenics (NASDAQ: AGEN), Color Kinetics (NASDAQ: CLRK) and EXACT Sciences (NASDAQ: EXAS).
In addition to being a Co-Founder and Director of LS9, Noubar currently serves as a Director for the following Flagship portfolio companies in which he is part of the founding team: Adnexus Therapeutics, Affinnova, BG Medicine, Codon Devices, Ensemble Discovery, Genstruct, Helicos BioSciences (NASDAQ:HLCS), T2 Biosystems. He is also engaged as an advisor with Flagship portfolio companies BIND Biosciences, Epitome Biosystems, and Mascoma. In addition, he is a member of the Boston University Board of Overseers and a member of several advisory boards including the Whitehead Institute at MIT, the Harvard-MIT Division of Health Sciences and Technology (HST), the Boston University Medical School and the Skolkovo School of Management in Moscow. He is also a founder/board member of Armenia 2020, an international economic development project focusing on the former Soviet Republic of Armenia. | 